NovaBridge Biosciences NBP
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
NovaBridge Biosciences (NBP) is a healthcare company listed in the US with a market value of about $98M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -31%.
About NovaBridge Biosciences
NovaBridge Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $4M in 2019 to $632000 in 2023, a decline of about 38.1% a year. It was profitable in 1 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $632000 | -$2M | $14M | $236M | $4M |
| Net income | -$46M | -$22M | -$208M | -$371M | -$366M | $72M | -$209M |
| Free cash flow | -$21M | -$53M | -$184M | -$162M | -$157M | $65M | -$126M |
| EPS (diluted) | $-0.40 | $-0.19 | $-1.80 | $-3.22 | $-3.17 | $0.63 | $-1.81 |
| Net margin | — | — | -32868.5% | 23923.5% | -2648.7% | 30.5% | -4840.1% |
| ROIC | -40.3% | -25.1% | -28.4% | -9.8% | -49.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does NovaBridge Biosciences pay a dividend?
Not currently.
Is NovaBridge Biosciences a good stock to buy?
We do not give buy or sell advice. NovaBridge Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.